Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)

01:00 EDT 11 Oct 2013 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
CIU is a skin condition characterized by red, swollen, itchy hives Currently, H1-antihistamines are the only approved therapy for patients suffering from CIU, also known as chronic spontaneous urticar...

Other Sources for this Article

Genentech
Media Contact:
Chris Vancheri, 650-467-6800
or
Investor Contacts:
Thomas Kudsk Larsen, 650-467-2016
Karl Mahler, 011 41 61 687 8503

NEXT ARTICLE

More From BioPortfolio on "FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story